Related Experiment Videos
Detection of minimal residual disease in acute myeloid leukemia
1Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. maria.baer@roswellpark.org
Abstract:
Acute myeloid leukemia (AML) is a curable malignancy, but its cure rate remains disappointingly low. Accurate quantitation of residual AML cells would allow individualization of therapy and thereby increase the likelihood of cure for each patient. Techniques that are being studied for residual disease detection include molecular assays for abnormalities that are present in subsets of AML patients, and multiparameter flow cytometry, which has broader applicability. Although significant advances have been made in the development of assays for monitoring residual disease, and particularly in techniques for molecular quantitation, additional refinement and validation are needed before these assays can be applied routinely in clinical management.
Insights
Accurate measurement of residual leukemia cells in acute myeloid leukemia (AML) can personalize treatment. Further validation of molecular and flow cytometry assays is needed for routine clinical use.
Area of Science:
- Hematology
- Oncology
- Molecular Diagnostics
Background:
- Acute myeloid leukemia (AML) is a curable cancer with a low cure rate.
- Individualizing therapy by quantifying residual AML cells could improve patient outcomes.
- Current residual disease detection methods include molecular assays and multiparameter flow cytometry.
Purpose of the Study:
- To review advances in residual disease detection for AML.
- To highlight the need for accurate quantitation of minimal residual disease (MRD).
- To discuss the potential of molecular assays and flow cytometry in AML management.
Main Methods:
- Review of current techniques for residual disease detection in AML.
- Focus on molecular assays and multiparameter flow cytometry.
- Discussion of the challenges in assay refinement and validation.
Main Results:
- Significant progress has been made in developing assays for monitoring residual AML.
- Molecular assays offer specific detection for certain AML subsets.
- Multiparameter flow cytometry provides broader applicability for residual disease detection.
Conclusions:
- Accurate quantitation of residual AML is crucial for personalized therapy.
- Molecular and flow cytometry assays show promise for monitoring residual disease.
- Further refinement and validation are required for routine clinical application of these assays.